Meeting Tue, 01/20/2026 - 12:00 Drug Prior Authorization Committee Meeting Information

Date
Media
Conduent Reports January 2026
New Drugs January 2026
DPAC Minutes January 2026 Approved
DPAC Minutes October 2025 Draft
Pharmacy January 2026
Pharmacy Benefit Administration Services Update January 2026
Edit Implementation Schedule for January 2026
PDL Recommendations January 2026
PDL Announcements April 2026
Agenda
DPAC Agenda January 2026
Criteria
DUR Criteria
Clinical and Fiscal Edits- Existing Criteria
Media
Antipsychotics - 1st Generation (Typical) Clinical Edit January 2026
Butalbital Combinations without Codeine Clinical Edit January 2026
Camzyos Clinical Edit January 2026
HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit January 2026
High Risk Therapies Clinical Edit January 2026
Journavx Clinical Edit January 2026
Morphine Milligram Equivalent Accumulation Clinical Edit January 2026
Selzentry Clinical Edit January 2026
Sohonos Clinical Edit January 2026
Verquvo Clinical Edit January 2026
Ztalmy Clinical Edit January 2026
DUR Criteria
Clinical and Fiscal Edits- New or Revised of Existing Criteria
Media
Anti-Amyloid Monoclonal Antibody Clinical Edit January 2026
Botulinum Toxin Clinical Edit January 2026
Corlanor Clinical Edit January 2026
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit January 2026
Duchenne Muscular Dystrophy (DMD) Clinical Edit January 2026
Enzyme Deficiency, Select Agents Clinical Edit January 2026
Opioids – Short-Acting Clinical Edit January 2026
Prior Authorization Required Fiscal Edit January 2026
Skyclarys Clinical Edit January 2026
Skysona Clinical Edit January 2026
DUR Criteria
Resource List – Existing Criteria
Media
Antipsychotics - 2nd Generation (Atypical) Depot Agents Resource List January 2026
DUR Criteria
Resource List - New or Revised Criteria
Media
Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents Resource List January 2026
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Antibiotics, Mupirocin Topical PDL Edit January 2026
Antibiotics, Vaginal PDL Edit January 2026
Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit January 2026
Anti-Parkinsonism, MAO-B Inhibitors PDL Edit January 2026
Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit January 2026
Cephalosporin Agents PDL Edit January 2026
Fibromyalgia Agents PDL Edit January 2026
Fluoroquinolones, Oral PDL Edit January 2026
Macrolides PDL Edit January 2026
Opioid and Select Alcohol Dependence Agents PDL Edit January 2026
Opioids, Long Acting PDL Edit January 2026
Penicillin Agents PDL Edit January 2026
Somatostatin Analogs PDL Edit January 2026
Tetracyclines PDL Edit January 2026
VMAT2-Inhibitors_January_2026_Proposal.docx
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Alzheimer’s Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists & Combinations PDL Edit January 2026
Antibiotics, Gastrointestinal (GI) Oral PDL Edit January 2026
Anticonvulsants, Dravet Syndrome PDL Edit January 2026
Antiemetics, 5-HT3 and NK1 Injectables PDL Edit January 2026
Anti-Migraine, Alternative Agents PDL Edit January 2026
Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit January 2026
Anti-Parkinsonism Non-Ergot Dopamine Agonists PDL Edit January 2026
Antiretroviral_Therapy_January_2026_Proposal.docx
GI Motility Agents, Chronic PDL Edit January 2026
Glucagon Agents PDL Edit January 2026
Hereditary Angioedema Agents PDL Edit January 2026
Neuropathic Pain Agents PDL Edit January 2026
NSAIDs PDL Edit January 2026
Opioid Emergency Reversal Agents PDL Edit January 2026
Sedative Hypnotics PDL Edit January 2026
Skeletal Muscle Relaxants PDL Edit January 2026
Tramadol-Like Agents PDL Edit January 2026
Page
Drug Prior Authorization Committee Meeting Information